Ericaf, a medication combining ergotamine and caffeine, is commonly used to help with acute and disruptive episodes of severe headache. This combination is applied in addressing conditions characterized by periods of heightened symptoms. The primary indications include migraine and vascular headaches.

This therapeutic approach is relevant for easing symptoms that interfere with daily functioning and create noticeable physiological strain. The drug is commonly used during phases when symptoms become temporarily overwhelming, and its use may be part of symptomatic management during acute episodes. By offering supportive relief in these crucial clinical scenarios, this medicine contributes to easing the overall symptom load and helps patients cope more steadily with symptom fluctuations.

Quick Fact: Supports Management of Physiological Strain

Regulatory References

1. NIH MedlinePlus Drug Information on Ergotamine and Caffeine

The eligibility for Ericaf (Ergotamine/Caffeine) is strictly defined by regulatory guidelines, primarily establishing use for adults who do not have documented contraindications. Use is restricted solely to the acute management of headaches and is not permitted for chronic daily administration.

Population Status	Regulatory Classification	Criteria Summary
Use Contraindicated	Absolute Prohibition	Pregnancy (Category X); Severe Hepatic or Renal Impairment; Vascular diseases including Coronary Artery Disease, Peripheral Vascular Disease, or uncontrolled Hypertension; Sepsis; and simultaneous use with potent CYP3A4 inhibitors (e.g., macrolide antibiotics).
Use Not Recommended	Insufficient Data / Limited Assessment	Pediatric patients (under 18 years), as safety and efficacy have not been established. Older adults (over 65 years), as use has not been systematically assessed.

This eligibility profile establishes that use is strictly defined by contraindications, prohibiting use in high-risk groups due to the risk of exacerbating existing vascular conditions or due to the risk of fetal harm. The medicine is not recommended for specific age groups where regulatory data is insufficient.

Interactions with other medicines and products

Ericaf (ergotamine and caffeine) has a specific interaction profile documented in regulatory sources, primarily structured by pharmacokinetic and pharmacodynamic constraints. The ergotamine component is a substrate of Cytochrome P450 3A4 (CYP 3A4), and its metabolic clearance is reduced by potent inhibitors of this enzyme.

Formal Contraindications

Co-administration is contraindicated with two main classes of interacting agents:

• Potent CYP 3A4 Inhibitors: This includes certain macrolide antibiotics (e.g., erythromycin, clarithromycin) and HIV protease inhibitors (e.g., ritonavir, nelfinavir). This interaction increases the blood levels of ergotamine, significantly raising the risk of acute ergot toxicity (ergotism), which may manifest as severe vasospasm.
• Other Vasoconstrictors: This category includes all 5HT₁ Receptor Agonists (Triptans) and other ergot alkaloids. This combination is prohibited due to the risk of enhanced vasoconstriction and subsequent ischemia.

Required Timing Separation and Other Interactions

Administration of Ericaf must be separated by 24 hours from the use of triptans or other ergot alkaloids. Pharmacodynamic interactions also exist with beta-blockers (e.g., propranolol), which can potentiate the vasoconstrictive action of ergotamine. Furthermore, the label notes that the use of nicotine and consumption of grapefruit juice can influence the systemic exposure or ischemic risk associated with ergotamine.

The action of this fixed-dose combination is achieved through a dual mechanism that targets the neural and vascular pathways, specifically focusing on the 5-HT and adenosine receptor systems.

Serotonergic Modulation and Neural Pathway Interruption

This mechanism centers on the primary agent, Ergotamine, which acts as an agonist on 5-HT1B and 5-HT1D serotonin receptors. Activation of 5-HT1D receptors on the trigeminal nerve terminals inhibits the release of pro-inflammatory peptides like CGRP. This molecular step initiates the suppression of neuropeptide release and contributes to the attenuation of neurogenic inflammation within the dura mater.

Dual-Action Vascular Tone Regulation

The drug modulates extracerebral vessel diameter through two complementary actions. Ergotamine directly activates vascular 5-HT1B receptors to induce smooth muscle contraction and vasoconstriction. Concurrently, Caffeine acts as an antagonist at A1 and A2A adenosine receptors, blocking adenosine’s natural vasodilatory effects and adding a second layer of vasoconstriction. This combined action results in a sustained reduction in the pulsation amplitude of the extracerebral cranial arteries.

Pharmacodynamic Synergy and Adjuvancy

The combination exhibits pharmacodynamic synergy, where Caffeine functions as an adjuvant, complementing the primary vascular and neural effects of Ergotamine. By adding its intrinsic central A1/2A antagonism, Caffeine complements the overall mechanism with mild central modulation and contributes to the degree of sustained vasoconstriction, supporting the disruption of the physiological event.

How Ericaf is Used: Official Administration Guidelines

Ericaf (ergotamine/caffeine) is a fixed-dose combination product intended solely for the acute, intermittent management of established headaches and is explicitly not for chronic, daily, or long-term use. This usage pattern defines the established scope of administration.

---

Administration and Dosage Limits

The medicine is officially approved for the oral route via tablet, though some labels also cover a rectal suppository form. The administration protocol is strictly time-sensitive, requiring adherence to the following thresholds:

Usage Constraint	Oral Tablet Regimen	Rationale
Starting Dose	2 tablets (2 mg Ergotamine) taken at the first sign of an attack.	To ensure the medication is initiated early in the episode.
Repeat Dosing	1 tablet may be taken every 30 minutes, if relief is not achieved.	To enforce the minimum required interval between doses.
Maximum Per Attack	A total of 6 tablets (6 mg Ergotamine).	Sets the ceiling for a single treatment episode.
Maximum Per 7 Days	A cumulative total of 10 tablets (10 mg Ergotamine).	Enforces the upper limit for intermittent use.

---

Usage Context

As an acute treatment, Ericaf is generally taken with water and may be administered with or without food. Because administration is determined by the onset of symptoms, the concept of a missed dose does not apply to this medication. Furthermore, the safety and efficacy of the combination have not been established for use in pediatric patients or for patients 65 years of age and older.

Evidence for Acute Treatment of Moderate to Severe Migraine Attacks

The core research for this combination involves studies applied in research contexts examining symptoms associated with episodic conditions, such as migraine. Most data was evaluated in adult patients experiencing acute or disruptive episodes of moderate to severe migraine pain. Researchers primarily focused on short-term randomized controlled trials (RCTs) and systematic reviews to evaluate symptom patterns.

The studies monitored several specific measures, including outcomes describing episodic or acute changes in headache intensity, such as the number of participants categorized by pain response or pain freedom two hours after administration. Findings describe patterns observed in the studies related to these short-term measurements, and research monitored patterns of headache recurrence in the 24 to 48 hours following the observation period. The evidence contributes to understanding symptom patterns but does not determine whether an individual will respond similarly.

---

Design of the Primary Clinical Trials

The evidence base for this combination includes studies conducted during periods of increased symptom activity. The designs involved comparisons against a placebo (an inactive substance) or against other compounds. The research primarily examined populations of healthy adult patients (18 to 65 years old). The study results reflect the specific conditions under which the research was conducted.

---

Long-Term Observations and Extended Use Patterns

Research exploring long-term outcomes and the durability of response over many months is generally limited. Consequently, the long-term effects are not fully established. Scientific literature has examined patterns of frequent use of the ergotamine component, highlighting that repeated administration was associated with the potential for developing a medication-overuse headache (MOH) and other long-term systemic conditions.

---

Evidence in Specific Patient Populations

The primary research for the combination focused on the general adult population. Data for certain groups remain insufficient. Evidence is limited for individuals outside the 18-to-65 age range, including both pediatric patients and older adults (geriatric). Knowledge about the effects of this combination in these specific populations remains uncertain.

---

Key Limitations and Areas of Uncertainty in the Research

Evidence quality varies across studies, as a substantial portion of the original research used methodologies that differ from those expected in modern clinical trials. The follow-up durations were limited primarily to short-term, acute observations, and comparative evidence is lacking in some modern trial settings. These limitations mean research provides context about group patterns but does not determine whether an individual will respond similarly.

Common questions about Ericaf (FAQ)

Q: Is there a generic version of Ericaf available?

A: Regulatory information indicates that generic versions of Ergotamine Tartrate and Caffeine tablets have been approved for use. These products contain the same active ingredients and are available under the generic name.

Q: What happens if I forget to take a dose of Ericaf?

A: According to official patient information, the concept of a 'missed dose' does not apply to this medicine. This is because Ericaf is an acute treatment, meaning it is taken only at the specific time when a headache begins, not on a fixed, scheduled daily basis.

Q: Is it common to feel tired when taking Ericaf?

A: Official safety profiles list side effects such as weakness and dizziness as common adverse reactions, which are effects on the central nervous system that may be related to feelings of being tired or having low energy. If these effects are severe, consultation with a healthcare provider is recommended.

Q: Does Ericaf interact with birth control pills?

A: Official labeling states that women should use an effective form of birth control while taking this medicine, primarily because it is contraindicated during pregnancy. Separately, official sources indicate the caffeine component may have a moderate interaction with the estrogen component found in some oral contraceptives.

Q: Can men and women use Ericaf in the same way?

A: Regulatory documents indicate that the use conditions and safety limits are universal for all Adults within the approved age range. The official information does not specify different administration instructions based on sex.

Q: How long is Ericaf typically taken for?

A: The official product label explicitly prohibits the medicine from being used for chronic daily administration. Use is strictly intended for the acute, intermittent management of severe headaches, meaning it is used only when an attack occurs.

Q: What information is included in the official Patient Information Leaflet for Ericaf?

A: Patient information sections in official labeling describe the drug's approved use and contraindications (who should not take it). They also detail the required limits on administration and provide instructions on which specific severe symptoms should be reported immediately to a physician.

Q: Does Ericaf need to be taken at a specific time of day?

A: Official patient information indicates that the medicine is directed to be taken at the first sign of a migraine headache. The timing of administration is therefore governed by the onset of symptoms, rather than by a fixed clock time like a daily prescription.

Q: What should I do if my side effects from Ericaf seem to get worse?

A: Official patient instructions describe the severe symptoms that warrant immediate reporting to a physician. These symptoms may include signs of serious vasospasm, such as numbness or tingling in the fingers and toes, muscle pain, or chest pain/tightness.

Q: Is Ericaf available in different strengths or forms (e.g., tablet, liquid)?

A: Regulatory documents describe the approved forms as an oral tablet and, in some international labels, a rectal suppository. These different forms typically contain a fixed combination of the active ingredients, Ergotamine and Caffeine.

Q: Are there any studies comparing the effects of Ericaf in different age groups?

A: Official regulatory documents note that the research evidence is explicitly designated as insufficient for use in both pediatric patients (under 18) and older adults (over 65). This indicates a lack of definitive comparison data for these age groups.

Q: What is the purpose of the initial testing a doctor performs before prescribing Ericaf?

A: The official contraindications for Ericaf prohibit its use in patients with certain vascular, liver (hepatic), or kidney (renal) conditions. The purpose of initial screening is described in the official warnings to rule out these pre-existing contraindications.

Q: If I switch from another drug to Ericaf, what should I expect?

A: The official product label mandates a 24-hour separation between Ericaf and other drugs in the same class, such as triptans or other ergot alkaloids. This time gap is required to reduce the risk of enhanced vasoconstriction.

Q: How reliable is the evidence base for Ericaf?

A: Official research sections acknowledge that the evidence base includes some studies that used older methodologies and had limited follow-up durations. This means that while the core efficacy is established, the data reflects specific limitations of the original research.

Q: Does Ericaf require special monitoring (e.g., blood tests)?

A: The regulatory label recommends that patients who use the medicine intermittently over a long period and who have or develop risk factors for heart disease undergo periodic interval cardiovascular evaluation. This evaluation is intended to monitor for potential vascular risks.

Q: Are there different brand names for the same medicine as Ericaf?

A: Regulatory label information often lists the generic name (Ergotamine/Caffeine) and associated brand names under which the product is or has been marketed. These names identify the same fixed-dose combination medicine.

The official labeling for Ericaf (Ergotamine Tartrate and Caffeine Tablets) provides specific requirements for storage and handling to ensure product stability.

Storage Conditions

• Temperature: The tablets must be stored at Controlled Room Temperature, which is defined as 20^circ to 25 C (68^circ to 77 F). Storage excursions are permitted between 15^circ and 30 C.
• Container and Protection: The medication must be dispensed and kept in a tight, light-resistant container. This requirement ensures necessary protection from both light exposure and excessive moisture.
• Child Safety: A mandatory instruction in the labeling states: KEEP OUT OF THE REACH OF CHILDREN.

Disposal Requirements

Unused or expired Ericaf tablets must be disposed of in accordance with local regulations or returned via an approved drug take-back program where such options are available. The product is not required to be handled as specialized hazardous pharmaceutical waste.